Clinical trial NCT05504499: REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
Official title: REFINE Study: A Prospective, Observational, Open-Label, Non-Randomized, Multi-Center Study Measuring Functional Outcomes In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lumbar Spinal Stenosis
Lead sponsor: Pacific Research Institute
Sponsor class: NETWORK
First posted: 2022-08-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This clinical investigation is a prospective, open-label, non-randomized, multi-center study. It is designed to collect clinical follow-up data on patients undergoing interspinous interlaminar fusion with bone graft performed on an ambulatory basis by interventional pain physicians, orthopedic, and neurosurgeons, as normally performed in the real-world setting.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.

Detailed description: INTRODUCTION

This study will evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in single-level fusion in patients with chronic low back pain that present with degenerative disc disease (DDD) with concurrent neurogenic claudication.

Devices included in study are the Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material. The device is a bilateral locking plate system which attaches to the spinous processes of the posterior noncervical spine (T1-S1) from an interlaminar approach. The implants have superior and inferior spinous process articulations and a central bone graft chamber.

The Aurora Spine ZIP™ is used to treat DDD (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies), spondylolisthesis, trauma (i.e., fracture or dislocation), and/or tumor. The studied indication is lumbar degenerative disease resulting in back pain with lower extremity symptoms and neurogenic claudication.

Degenerative disc disease is a common condition of the aging spine, and may contribute to a variety of painful symptoms, including radiculopathy, neurogenic claudication, and back pain. There are a number of mechanical sequelae that result from these degenerative processes of the intervertebral disc, which may manifest in the anterior, middle, and posterior columns of the spine. Symptoms of degenerative disc disease have traditionally been treated with a variety of conservative (pain medications, physical therapy, epidural steroid injections) and invasive (surgical decompression and/or fusion) options(1,2). Interspinous spacers (ISS) have been proven to be effective for neurogenic claudication with 5 year outcome data and robust clinical experience (3). More invasive treatment options for lumbar spinal stenosis include decompressive laminectomies and a variety of approaches to lumbar fusion.

Direct comparison of two year results of ISS and decompressive laminectomies found ISS offers a less invasive treatment that reduces the potential for comorbidities, necessity for future operations, and is less disruptive to the spinal anatomy providing greater options for future surgical interventions with equivalent clinical outcomes (4). The landmark multicenter SPORT trial compared decompressive laminectomy to conservative non-operative care in patients with spinal stenosis with neurogenic claudication and found that the surgical group had significantly greater improvement in pain and function at four-year follow-up (5).

A meta-analysis of lumbar fusions for degenerative diseases looked at patient reported outcomes from 65 studies including disability, pain scores, and patient satisfaction. Fusion has been shown to be evidenced for spondylolisthesis, and patients who were randomly assigned to fusion care were 4 times as likely to be satisfied, attained 34% greater pain relief and saw a 40% improvement of preoperative disability when compared to those who received non-operative care (2). Evidence for fusion for stenosis without spondylolisthesis is limited in this meta-analysis, however this did not distinguish among fusion approaches.

Fusion did provide greater relief than non-operative care in patients with chronic low back pain without clinically significant stenosis or spondylolisthesis (2). Five randomized control trials reported results with fusion between 16-18% improved in terms of back and leg pain as compared to non-operative care (2). Anterior interbody fusion (ABF) and posterolateral fusion with pedicle screws (PLF) in patients with discogenic low back pain resulted in a significant decrease in VAS pain scores, with greatest relief following ABF, compared to conservative treatment (6).

3 STUDY PURPOSE

The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in single-level fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.

Eligibility criteria: Inclusion Criteria:

* Subjects enrolled in this study must meet ALL of the following inclusion criteria:

  1. Subject must provide written informed consent prior to any clinical study-related procedure.
  2. Subject is at least 18 years or older at the time of enrollment, skeletal mature.
  3. Subject has 1-2 symptomatic lumbar degenerative disease at adjacent level, T12-S1, with or without grade I spondylolisthesis (confirmed by history and radiographic studies).
  4. MRI within 12 months prior to the procedure with at least mild to moderate spinal stenosis at the index treatment level
  5. Subject has undergone at least 3 months of non-operative treatment.
  6. Subject presents with ZCQ physical function ≥ 2.0 at baseline.
  7. Subject reports relief from lumbar flexion and/or sitting.
  8. Subject has baseline VAS of back and/or leg pain standing or walking ≥ 50mm.

Exclusion Criteria:

* Subjects enrolled in this study must NOT meet any of the following exclusion criteria:

  1. Subject is unable to provide written informed consent.
  2. Subject has had previous lumbar spine surgery at the intended treatment level (e.g., laminectomy or fusion).
  3. Subject has a grade II or greater spondylolisthesis on flexion and extension radiographs with 3mm instability.
  4. Subject has confirmed or suspected osteoporosis or osteopenia.
  5. Subject is enrolled, or intends to participate, in a clinical drug and/or device study (investigational device, investigational drug, new indication for a device or drug, or additional testing beyond standard of care procedures) which could confound the results of this trial as determined by the investigator.
  6. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.
  7. Subject is pregnant or nursing.

Primary outcomes:
measure: To evaluate the efficacy and safety of the Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material based on improvement in composite endpoints relative to baseline at 3 and 12 months 1. > 20mm pain reduction in VAS Back while standing
timeFrame: 12 months
Secondary outcomes:
measure: • To demonstrate real-world evidence of a significant improvement in the Pain Impact Score using ZIP™ as measured by the PROMIS-29 relative to baseline at 3 and 12 months.
timeFrame: 12 months
measure: • To identify patterns related to the influence of pharmacologic agents on response to therapy (and vice versa).
timeFrame: 12 months
measure: To characterize patient global impression of change (PGIC) relative to baseline at 3 and 12 months.
timeFrame: 12 months
measure: Imaging analysis
timeFrame: 12 months
measure: Complication Rate
timeFrame: 12 months
measure: Complication Rate
timeFrame: 12 months
Other outcomes:
Locations:
city: Santa Rosa
country: United States
facility: Evolve Restorative Center
state: California
city: Jupiter
country: United States
facility: The Raso Pain Center
state: Florida
city: Slidell
country: United States
facility: Koga Neurosurgery
state: Louisiana
city: Oxon Hill
country: United States
facility: National Spine and Pain Centers
state: Maryland
city: Henderson
country: United States
facility: Comprehensive & Interventional Pain Management
state: Nevada
city: Reno
country: United States
facility: Nevada Advanced Pain Specialists
state: Nevada
city: Reno
country: United States
facility: Reno Tahoe Pain Associates
state: Nevada
city: Voorhees
country: United States
facility: The Pain Management Center
state: New Jersey
city: Loveland
country: United States
facility: Premier Pain Treatment Institute
state: Ohio
city: Chadds Ford
country: United States
facility: Center for Interventional Pain and Spine
state: Pennsylvania
Study officials:
References:
citation: Falowski SM, Raso LJ, Mangal V, Narizi A, Patterson DG, Danko MD, Justiz R, Vogel RS, Koga S, Josephson Y, Pope JE. A Prospective, Observational, Open-Label, Non-Randomized, Multicenter Study Measuring Functional Outcomes in a Novel Interspinous Fusion Device in Subjects with Low Back Pain: REFINE Study. Pain Ther. 2023 Feb;12(1):187-199. doi: 10.1007/s40122-022-00447-0. Epub 2022 Oct 20.